Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) and Beauty Health (NASDAQ:SKIN – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, risk, dividends and valuation.
Risk and Volatility
Vivos Therapeutics has a beta of 7.47, meaning that its share price is 647% more volatile than the S&P 500. Comparatively, Beauty Health has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500.
Insider & Institutional Ownership
26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 93.3% of Beauty Health shares are held by institutional investors. 3.0% of Vivos Therapeutics shares are held by insiders. Comparatively, 41.0% of Beauty Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Vivos Therapeutics | -86.19% | -335.04% | -93.58% |
| Beauty Health | -8.11% | -44.83% | -3.54% |
Earnings and Valuation
This table compares Vivos Therapeutics and Beauty Health”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vivos Therapeutics | $14.58 million | 1.49 | -$13.58 million | ($5.68) | -0.65 |
| Beauty Health | $347.62 million | 0.46 | -$100.12 million | ($0.42) | -3.10 |
Vivos Therapeutics has higher earnings, but lower revenue than Beauty Health. Beauty Health is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings for Vivos Therapeutics and Beauty Health, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vivos Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| Beauty Health | 1 | 3 | 1 | 0 | 2.00 |
Vivos Therapeutics currently has a consensus price target of $6.30, indicating a potential upside of 70.73%. Beauty Health has a consensus price target of $2.55, indicating a potential upside of 96.15%. Given Beauty Health’s higher possible upside, analysts plainly believe Beauty Health is more favorable than Vivos Therapeutics.
Summary
Beauty Health beats Vivos Therapeutics on 8 of the 14 factors compared between the two stocks.
About Vivos Therapeutics
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.
About Beauty Health
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.
Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
